At Resonant, our team of researchers, physicians, and business leaders is united by a shared mission: to translate innovative research into impactful clinical solutions.
We foster a culture of empathy, collaboration, and innovation, ensuring everything we do centers on advancing patient care.
Chad leads the company with a deep commitment to advancing genomic research through innovative sequencing technologies. Chad drives the strategic vision of the company, fostering growth and delivering cutting-edge solutions for researchers and clinical providers.
Steve brings over 15 years of expertise in genomics and biotechnology operations, with notable experience as VP of Lab Operations at Flagship Biosciences and Director of Global Genomics Lab Operations and Business Development at Q² Solutions.
Bruce brings over 25 years of experience in technology leadership, with a career spanning from launching multiple startups to engineering world-class emergency communication systems. Passionate about developing intuitive and highly reliable software, he thrives on creating seamless user experiences.
Tim, an Associate Professor of Cell Biology and Physiology at BYU, leverages the power of epigenetics as a clinically actionable diagnostics tool. His work extends to include common and severe diseases, male fertility, Alzheimer’s, cancer, and forensics.
Jonathon, an Associate Professor of Cell Biology and Physiology at BYU, develops innovative genomic and bioinformatic methods for gene expression analysis and variant detection. He studies the molecular genetics of congenital heart defects in his lab.
Dean Lilley is the Director of Product and Marketing at Resonant, where he brings the same energy and focus he’s honed from years of outdoor adventures and mountain sports. Whether he’s planning a bike ride or launching a new product, Dean knows the value of thinking ahead, sweating the small stuff, and executing with precision.
As Director of Business Development at Resonant, Alan leverages 28 years of business development and technology adoption strategy. He is responsible for forging commercial partnerships and establishing a robust ecosystem of biotechnology partners.
Joe is a dynamic quality leader who pushes excellence within the biotech industry. His expertise in Clinical Laboratories, Medical Devices, and Quality Systems isn't just a skill set – it's a strategic advantage, enabling robust solutions and precision decision-making.
Dr. Erin Saito, Director of Medical Writing at Resonant, drives the creation of impactful content that bridges complex science with clear communication. With a strong background in neuroscience and metabolic physiology research, she leads initiatives that align with company goals while fostering collaboration and mentorship.
With over a decade of experience in the biotech industry, Ryan brings a wide breadth of expertise to the Resonant team - from genetic analysis, to assay development, and building computational pipelines and infrastructure. His most recent focus has been developing cutting-edge epigenetic-based assays, with applications ranging from liquid biopsies to male fertility diagnostics.
Isaac is a full-spectrum scientist with expertise across the product development pipeline—from experimental design and implementation to advanced data analysis. With a strong background in genomics, epigenomics, translational science, and data science, he brings a systems-level perspective to solving complex biological problems.
As a Research Associate at Resonant, Andrew drives internal research and development, connecting clients with cutting-edge solutions. He is passionate about scientific discovery and dedicated to designing and validating innovative technologies to overcome complex sequencing challenges in the clinical field.
Kelaney is a Project Manager at Resonant, where she combines her background in epigenetic research with a passion for problem-solving. With a knack for tackling complex challenges—whether in the lab or on a hiking trail—she knows the importance of curiosity, persistence, and a well-thought-out plan.
As our Senior Designer, he specialize in a diverse range of design disciplines, from art direction in brand identity to managing comprehensive design systems. His expertise spans the creation of websites, logos, environmental design, and visual identities. Driven by a passion for creative excellence, Andrew evaluates and develop diverse, bespoke design strategies based on in-depth conceptual exploration and client briefs for our companies.
Integrity lies at the core of how we conduct our research, manage our business, and interact with each other and the communities we serve. This means upholding high ethical standards, being honest in our communications, and embracing responsibility in our decisions and their impacts.
Our commitment to innovation drives us to develop more effective solutions for patients with neurodegenerative diseases. We embrace leading technologies and novel research methodologies to create solutions with the potential to expedite diagnoses and significantly improve patient outcomes.
Empathy guides our approach to healthcare. We are dedicated to understanding and addressing the needs of patients, families, and caregivers affected by neurodegenerative diseases. This commitment not only influences our product development, but also the way we support each other within our team.
Our goal is to empower patients. We are developing tools to detect biomarkers of neurodegeneration earlier in disease progression. But these tools aren't just about detecting diseases earlier. They're about giving control back to the patients, empowering them to make informed decisions that enhance their quality of life.
We prioritize thorough validation of our tests to ensure that healthcare professionals and patients can make informed decisions based on dependable test results. Our rigorous approach supports better health outcomes, disease management, and treatment planning.
